Moderna Stock: Share Price, Results and Analysis 2026

This profile covers Moderna (MRNA), a healthcare company in messenger RNA biotechnology. The mRNA platform of the pandemic is reinventing itself (combined respiratory vaccines, cancer). In 2025, revenue collapsed to $1.9 billion with a loss of $2.8 billion — cash ($6.8 billion net) is funding the transition. If you are considering whether to buy Moderna stock, the key figures are below.

The figures below come from the latest published financial statements (S&P data verified in November 2026). They cover the last three fiscal years, the dividend policy and the key decision points for a French-speaking investor.

Stock Profile

CompanyModerna
MarketNASDAQ (MRNA) — standard securities account (CTO), W-8BEN.
ISINUS60770K1079
SectorHealthcare — messenger RNA biotechnology
Reporting currencyUS dollars
Dividend (latest fiscal year)No dividend paid

Results for the Last Three Fiscal Years

Fiscal yearRevenueNet income
2025$1.94bn-$2.82bn
2024$3.24bn-$3.56bn
2023$6.85bn-$4.71bn

The net cash position stands at $6.83bn: a debt-free balance sheet.

Moderna Dividend Policy

For the last full fiscal year, no dividend per share was paid. If a dividend is introduced, check the ex-dividend calendar (usually announced with the annual results) and the applicable tax treatment: withholding tax in the issuer’s country, which can be credited in France within the limits of tax treaties.

Tableau originalDiversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

Strengths

  • A unique, proven mRNA platform
  • Pipeline in cancer and rare diseases
  • Net cash of $6.8 billion

Risks to Watch

  • Net loss of $2.8 billion a year
  • Dependence on the success of the 2026 combined vaccines
  • Competition from Pfizer and GSK

Conclusion: Moderna is a speculative option on RNA medicine, best held in a small position.

Reading These Figures Like an Investor

Three habits help you get the most out of the table above. First, the revenue trend over three fiscal years: steady growth signals a strong franchise, while erosion calls for an explanation (cycle, lost market share, divestment). Next, the conversion into net income: the net margin reveals pricing power and cost discipline — compare it year over year rather than across companies. Finally, net cash: a cash-rich balance sheet creates options (buybacks, acquisitions, special dividends), while net debt means checking that operating income comfortably covers interest. Add to this the dividend yield (dividend divided by share price) and how well earnings cover it: a dividend covered more than twice can withstand bad years. Taken together, these four indicators turn a profile like this one into a real decision-making tool — to be cross-checked against the group’s quarterly reports to spot turning points before the consensus does.

How to Buy Moderna Stock from France

Open a securities account (or a PEA for eligible European listings) with a regulated broker, fund the account, then place a limit order on the ticker shown in the profile. For stocks listed outside Europe, the W-8BEN form reduces US withholding tax on dividends to 15%. CFD brokers such as Vantage, this site’s reference broker, also let you trade both rising and falling prices through contracts for difference — leverage requires strict risk management.

Practical steps: 1) compare three regulated brokers on trading and currency conversion fees; 2) open the account and verify your identity; 3) fund it by bank transfer; 4) place a first limit order of reasonable size; 5) note the date of the next ex-dividend; 6) review the position at every earnings release. Regular scheduled investments smooth out the risk of bad timing better than any attempt to predict the market.

Frequently Asked Questions

Where is Moderna listed?

NASDAQ (MRNA) — standard securities account (CTO), W-8BEN.

Does Moderna pay a dividend?

No dividend is currently paid.

Is Moderna eligible for a PEA?

Not for the main listing cited here: the stock is held in a standard securities account (CTO). Check the PEA eligibility of the European listing where the group has one.

What is Moderna’s ISIN?

US60770K1079

What are the upcoming key dates?

The annual and quarterly results published by the group are the main catalysts for the stock — follow the financial calendar on Moderna’s investor relations website.

This page is provided for information purposes only and does not constitute investment advice. Past performance is not a reliable indicator of future results; any stock market investment carries a risk of capital loss.

Suivez-nous sur Telegram